Due to the removal of primary tumors from most patients soon after diagnosis, the utilization of anti-EP receptor therapy would be a beneficial treatment in targeting metastatic breast tumor cells overexpressing COX2. This evidence concerns the gene PTGS2 and breast neoplasm.